Cerevel Therapeutics Announces the Appointments of Deval Patrick and Deborah Baron to its Board of Directors
January 21, 2021 07:00 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has...
Cerevel Therapeutics to Host Inaugural Virtual R&D Event
December 14, 2020 07:00 ET
|
Cerevel Therapeutics
Event will focus on CVL-865, the Phase 2 GABA Positive Allosteric Modulator, and include an overview of key preclinical programs Live webcast scheduled for Thursday, January 28 from 9:00 to 11:00...
Cerevel Therapeutics Announces the Appointment of Dr. Ruth McKernan to its Board of Directors
December 08, 2020 07:00 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today...
Cerevel Therapeutics to Host Investor Webcast Moderated by Stifel
December 04, 2020 07:00 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it...
Cerevel Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
November 23, 2020 07:00 ET
|
Cerevel Therapeutics
BOSTON, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced Chairperson and...
Cerevel Therapeutics Announces Third Quarter 2020 Financial Results and Key Business Highlights
November 16, 2020 06:30 ET
|
Cerevel Therapeutics
Participants dosed in clinical trials for lead programs in schizophrenia, epilepsy, anxiety and Parkinson’s disease Debuted as publicly traded entity under symbol CERE ...
Cerevel Therapeutics to Present at Upcoming Virtual Investor Conferences
November 04, 2020 07:00 ET
|
Cerevel Therapeutics
BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of...
Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 Trials of Tavapadon for the Treatment of Parkinson’s Disease
October 30, 2020 07:00 ET
|
Cerevel Therapeutics, LLC
BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that the...
Cerevel Therapeutics Debuts as Publicly Traded Neuroscience Company
October 28, 2020 07:00 ET
|
Cerevel Therapeutics, LLC
Business combination transaction with Arya Sciences Acquisition Corp II, a special purpose acquisition company sponsored by Perceptive Advisors, completed on October 27, 2020 Combined company renamed...